- Home
- GNPX vs SNTG Comparison
GNPX vs SNTG Comparison
Compare GNPX & SNTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GNPX | SNTG |
|---|---|---|
| Founded | 2009 | 2009 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4M | 6.1M |
| IPO Year | 2017 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GNPX | SNTG |
|---|---|---|
| Price | $2.00 | $1.90 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 852.6K | 25.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 76.33 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.14 | $1.43 |
| 52 Week High | $12.97 | $12.70 |
Technical Indicators
Market Signals| Indicator | GNPX | SNTG |
|---|---|---|
| Relative Strength Index (RSI) | 46.07 | 42.64 |
| Support Level | $1.90 | $1.86 |
| Resistance Level | $2.51 | $1.96 |
| Average True Range (ATR) | 0.20 | 0.07 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 32.89 | 20.00 |
Price Performance
Historical ComparisonAbout GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
About SNTG Sentage Holdings Inc.
Sentage Holdings Inc is a financial service provider that offers a comprehensive range of financial services across consumer loan repayment and collection management, loan recommendation, and prepaid payment network services in China.